ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1357

Anti-Cyclic Citrullinated Peptide Antibody Positive Rheumatoid Arthritis Patients with Comorbid Post-Traumatic Stress Disorder Have Higher Serum Cytokine Expression

Bryant R. England1, Harlan Sayles2, Geoffrey M. Thiele2, Kaleb Michaud2, Jeremy Sokolove3, Grant Cannon4, Andreas Reimold5, Gail S. Kerr6, Liron Caplan7, Joshua Baker8 and Ted R. Mikuls9, 1Division of Rheumatology & Immunology, Department of Internal Medicine, Nebraska-Western IA VA Health Care System & University of Nebraska Medical Center, Omaha, NE, 2University of Nebraska Medical Center, Omaha, NE, 3Division of Immunology and Rheumatology, Stanford University Medical Center, Mountain View, CA, 4Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, 5Hospital of Southern Norway, Kristiansand, Norway, 6VAMC, Georgetown University, Washington, DC, 7Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO, 8Rheumatology, University of Pennsylvania, Philadelphia, PA, 9Internal Medicine, Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: cytokines and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 6, 2017

Title: Rheumatoid Arthritis – Clinical Aspects Poster II: Pathophysiology, Autoantibodies, and Disease Activity Measures

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: We have previously shown that rheumatoid arthritis (RA) patients with Post-Traumatic Stress Disorder (PTSD) have higher disease activity measures, due primarily to patient reported measures including higher tender joint counts, pain, and worse patient global scores. However, a recent systematic review and meta-analysis reported increased serum expression of IL-1, IL-6, and IFN-γ in PTSD patients (Passos IC et. al., Lancet Psychiatry, 2015). The purpose of this study was to compare serum cytokine/chemokine expression in RA patients with and without PTSD.

Methods: Participants were enrollees in a multicenter, longitudinal observational cohort of US Veterans with RA categorized as having PTSD, other anxiety or depression, or neither based on administrative codes. Serum cytokines/chemokines were measured from banked serum at enrollment using a multiplex bead-based assay. Cytokines (CKs) were modeled using an overall cytokine (CK) score (log-transformed), the number of elevated cytokines (>2 SD above mean), and by individual CKs (log-transformed). CK score and number of elevated CKs were compared between groups using ANOVA and Χ2. The association of PTSD with CK parameters was assessed using multivariable least squares and negative binomial regression adjusted for age, sex, race, and smoking status. Analyses were additionally stratified by anti-CCP status.

Results: Of 1,460 RA subjects with mean (SD) age of 64 (11) years, RA duration 11 (11) years, were 91% male, 76% anti-CCP positive, and 80% current or former smokers, 9% had PTSD, 24% had other depression/anxiety, and 67% had neither psychiatric condition. In unadjusted comparisons, those with PTSD had higher CK scores (P=0.02) and a greater number of elevated CKs (P=0.02, Figure 1). In multivariable least squares and negative binomial regression models, CK score and number of positive CKs were associated with PTSD, though this was limited to those who were anti-CCP positive (Table 1). Anxiety/depression subjects without PTSD had similar CK scores and number of elevated CKs as controls. PTSD was associated with heightened expression of several individual CKs (IL-1, IL-2, IL-6, IL-10, GM-CSF, IFN-γ, MCP-1).

Conclusion: Anti-CCP positive RA patients with PTSD have a higher serum cytokine expression in comparison to those without PTSD. These findings support an objective measure of increased inflammation in RA patients with comorbid PTSD. Exploration of a potential mechanistic inflammatory link between RA and PTSD and contributions of specific cytokines will require future study.

 

Table 1. Associations of Serum Cytokines with PTSD in Rheumatoid Arthritis

 

No Depression, Anxiety or PTSD

Depression or Anxiety

PTSD

Values, mean (SD)

 

 

 

Cytokine score

2.33 (0.89)

2.39 (0.91)

2.56 (0.93)

Cytokine number positive

1.08 (2.23)

1.23 (2.42)

1.64 (2.75)

All subjects±

 

 

 

Cytokine score

Reference

0.055 (-0.055, 0.165)

0.193 (0.026, 0.361)*

Cytokine number positive

Reference

0.145 (-0.051, 0.341)

0.355 (0.197, 0.513)**

Anti-CCP positive±

 

 

 

Cytokine score

Reference

-0.027 (-0.170, 0.117)

0.193 (-0.018, 0.405)

Cytokine number positive

Reference

-0.036 (-0.272, 0.201)

0.339 (0.162, 0.517)**

Anti-CCP negative±

 

 

 

Cytokine score

Reference

-0.048 (-0.266, 0.171)

-0.074 (-0.410, 0.261)

Cytokine number positive

Reference

0.184 (-0.403, 0.771)

-0.233 (-0.588, 0.092)

±Values represent b coefficients (95% confidence interval)

*P < 0.05; ** P <0.01

Models adjusted for age, sex, race, and smoking status.

 


Disclosure: B. R. England, None; H. Sayles, None; G. M. Thiele, None; K. Michaud, None; J. Sokolove, None; G. Cannon, Amgen, 2; A. Reimold, Bristol-Myers Squibb, 2,Janssen Pharmaceutica Product, L.P., 2,Pfizer, 2,Human Genome Sciences, 2,Novartis, 2; G. S. Kerr, Janssen, BMS, Genetech, Pfizer, 2; L. Caplan, None; J. Baker, None; T. R. Mikuls, BMS, 2,Ironwood Pharm, 2,Pfizer Inc, 5,NIH, VA, 2.

To cite this abstract in AMA style:

England BR, Sayles H, Thiele GM, Michaud K, Sokolove J, Cannon G, Reimold A, Kerr GS, Caplan L, Baker J, Mikuls TR. Anti-Cyclic Citrullinated Peptide Antibody Positive Rheumatoid Arthritis Patients with Comorbid Post-Traumatic Stress Disorder Have Higher Serum Cytokine Expression [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/anti-cyclic-citrullinated-peptide-antibody-positive-rheumatoid-arthritis-patients-with-comorbid-post-traumatic-stress-disorder-have-higher-serum-cytokine-expression/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/anti-cyclic-citrullinated-peptide-antibody-positive-rheumatoid-arthritis-patients-with-comorbid-post-traumatic-stress-disorder-have-higher-serum-cytokine-expression/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology